FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Hawaii Biotech: Phase I West Nile vax trial a success

  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Hawaii Biotech announced the successful completion of a Phase I clinical trial for its West Nile Virus vaccine. The recombinant sub-unit vaccine was found to be safe among healthy volunteers who had not been exposed to the virus. The company says it is preparing to proceed with additional safety studies in adults, and later plans to expand the studies to include elderly, juvenile and immunocompromised populations.

"We are extremely pleased with the safety results of our West Nile Virus vaccine Phase 1 study and are encouraged by the presence of neutralizing antibodies in all individuals receiving the formulated vaccine," noted president and CEO Dr. Elliot Parks. "Additionally, these results demonstrate the robustness of our protein production platform for the development of additional sub-unit vaccines in our product pipeline."

- check out the Hawaii Biotech release for more

Related Article:
Hawaii Biotech moves West Nile vaccine into clinic

More stories about West Nile Virus   West Nile Vaccine   phase I   Hawaii Biotech   Clinical Trial Results  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.